Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,639.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $2,639.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,639.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $2,639.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835545359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

356 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $61.00 12/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030559
Principal investigator 1 Incyte Corporation $95.00 12/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666473035
Principal investigator 1 EMD Serono, Inc. $61.00 11/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030543
Principal investigator 1 Incyte Corporation $9,748.80 11/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459681
Principal investigator 1 Incyte Corporation $89,053.20 11/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459675
Principal investigator 1 Incyte Corporation $57,932.10 11/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459677
Principal investigator 1 Incyte Corporation $61.84 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459487
Principal investigator 1 Incyte Corporation $14.20 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459489
Principal investigator 1 Incyte Corporation $70.32 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459491
Principal investigator 1 Incyte Corporation $191.00 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459493
Principal investigator 1 Incyte Corporation $6.40 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459509
Principal investigator 1 Incyte Corporation $28.65 11/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459511
Principal investigator 1 EMD Serono, Inc. $1,621.80 11/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703034305
Principal investigator 1 Incyte Corporation $95.00 11/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666473033
Principal investigator 1 Merck Sharp & Dohme Corporation $203,484.00 11/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 691538153
Principal investigator 1 EMD Serono, Inc. $61.00 10/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030535
Principal investigator 1 Incyte Corporation $14,676.77 10/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies No dispute reported 06/30/2026 666458805
Principal investigator 1 Incyte Corporation $56,531.70 10/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $768.00 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,781.52 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,456.84 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $190.08 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,140.00 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,607.76 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/23/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 639740675
Principal investigator 1 Incyte Corporation $500.00 10/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458803
Principal investigator 1 Incyte Corporation $30,842.10 10/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459669
Principal investigator 1 Incyte Corporation $185.52 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459315
Principal investigator 1 Incyte Corporation $58.50 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459431
Principal investigator 1 Incyte Corporation $7.10 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459433
Principal investigator 1 Incyte Corporation $1.20 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459435
Principal investigator 1 Incyte Corporation $9.92 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459437
Principal investigator 1 Incyte Corporation $123.68 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459439
Principal investigator 1 Incyte Corporation $175.80 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459441
Principal investigator 1 Incyte Corporation $329.45 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459443
Principal investigator 1 Incyte Corporation $38.70 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459445
Principal investigator 1 Incyte Corporation $2.56 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459447
Principal investigator 1 Incyte Corporation $188.00 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459449
Principal investigator 1 Incyte Corporation $76.40 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459451
Principal investigator 1 Incyte Corporation $169.44 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459453
Principal investigator 1 Incyte Corporation $48.48 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459455
Principal investigator 1 Incyte Corporation $5.04 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459457
Principal investigator 1 Incyte Corporation $14.08 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459459
Principal investigator 1 Incyte Corporation $162.72 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459461
Principal investigator 1 Incyte Corporation $76.40 10/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459499
Principal investigator 1 Incyte Corporation $95.00 10/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666473031
Principal investigator 1 EMD Serono, Inc. $61.00 09/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030519
Principal investigator 1 Incyte Corporation $355,021.30 09/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459563
Principal investigator 1 Incyte Corporation $1,113.31 09/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459565
Principal investigator 1 Incyte Corporation $12,829.00 09/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459561
Principal investigator 1 Incyte Corporation $20.26 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459219
Principal investigator 1 Incyte Corporation $9.55 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459221
Principal investigator 1 Incyte Corporation $131.78 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459223
Principal investigator 1 Incyte Corporation $105.48 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459225
Principal investigator 1 Incyte Corporation $565.74 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459227
Principal investigator 1 Incyte Corporation $76.40 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459247
Principal investigator 1 Incyte Corporation $84.72 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459249
Principal investigator 1 Incyte Corporation $70.32 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459251
Principal investigator 1 Incyte Corporation $188.00 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459253
Principal investigator 1 Incyte Corporation $61.84 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459255
Principal investigator 1 Incyte Corporation $24.24 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459257
Principal investigator 1 Incyte Corporation $5.04 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459259
Principal investigator 1 Incyte Corporation $7.04 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459261
Principal investigator 1 Incyte Corporation $117.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459263
Principal investigator 1 Incyte Corporation $58.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459265
Principal investigator 1 Incyte Corporation $211.80 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459267
Principal investigator 1 Incyte Corporation $45.45 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459269
Principal investigator 1 Incyte Corporation $6.30 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459271
Principal investigator 1 Incyte Corporation $101.70 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459273
Principal investigator 1 Incyte Corporation $13.20 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459275
Principal investigator 1 Incyte Corporation $76.40 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459291
Principal investigator 1 Incyte Corporation $76.40 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459293
Principal investigator 1 Incyte Corporation $131.78 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459295
Principal investigator 1 Incyte Corporation $76.40 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459297
Principal investigator 1 Incyte Corporation $117.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459299
Principal investigator 1 Incyte Corporation $58.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459301
Principal investigator 1 Incyte Corporation $58.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459303
Principal investigator 1 EMD Serono, Inc. $3,243.60 09/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703035285
Principal investigator 1 EMD Serono, Inc. $62,525.00 09/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS201408-0005 No dispute reported 06/30/2026 703037211
Principal investigator 1 Incyte Corporation $95.00 09/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472827
Principal investigator 1 EMD Serono, Inc. $61.00 08/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030503
Principal investigator 1 AstraZeneca Pharmaceuticals LP $158,664.50 08/26/2019 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Basket Study (Ph2a) No dispute reported 06/30/2026 685003967
Principal investigator 1 Incyte Corporation $87.50 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500931
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500933
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500935
Principal investigator 1 Incyte Corporation $87.50 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501065
Principal investigator 1 Incyte Corporation $87.50 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501067
Principal investigator 1 Incyte Corporation $87.50 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501069
Principal investigator 1 Incyte Corporation $87.50 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501071
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501073
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501075
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501077
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501079
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501081
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501083
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501085
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501087
Principal investigator 1 Incyte Corporation $105.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501089
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501091
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501093
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501095
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501097
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501099
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501101
Principal investigator 1 Incyte Corporation $8.00 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501103
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501105
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501107
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501109
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501111
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501113
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501115
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501153
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501155
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501157
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501159
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501161
Principal investigator 1 Incyte Corporation $5.60 08/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501163
Principal investigator 1 Incyte Corporation $1,875.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459401
Principal investigator 1 Incyte Corporation $500.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459403
Principal investigator 1 Incyte Corporation $169.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459405
Principal investigator 1 Incyte Corporation $180.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459407
Principal investigator 1 Incyte Corporation $625.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459409
Principal investigator 1 Incyte Corporation $3,475.19 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459411
Principal investigator 1 Incyte Corporation $780.00 08/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459413
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500929
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501043
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501045
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501047
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501049
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501051
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501053
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501055
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501057
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501059
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501061
Principal investigator 1 Incyte Corporation $5.60 08/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501063
Principal investigator 1 Incyte Corporation $29,771.10 08/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459397
Principal investigator 1 Incyte Corporation $39,553.20 08/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459399
Principal investigator 1 Incyte Corporation $95.00 08/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472825
Principal investigator 1 EMD Serono, Inc. $61.00 07/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703030487
Principal investigator 1 Incyte Corporation $22,253.00 07/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459393
Principal investigator 1 Incyte Corporation $725.40 07/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459395
Principal investigator 1 Merck Sharp & Dohme Corporation $132,942.88 07/19/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 691517483
Principal investigator 1 Incyte Corporation $2,037.05 07/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458789
Principal investigator 1 Incyte Corporation $1,572.62 07/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458791
Principal investigator 1 Incyte Corporation $4,478.05 07/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458793
Principal investigator 1 Incyte Corporation $64,252.70 07/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458797
Principal investigator 1 Incyte Corporation $47.75 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459199
Principal investigator 1 Incyte Corporation $211.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459201
Principal investigator 1 Incyte Corporation $23.40 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459203
Principal investigator 1 Incyte Corporation $140.40 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459205
Principal investigator 1 Incyte Corporation $105.30 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459207
Principal investigator 1 Incyte Corporation $46.80 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459209
Principal investigator 1 Incyte Corporation $11.34 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459211
Principal investigator 1 Incyte Corporation $413.01 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459213
Principal investigator 1 Incyte Corporation $54.54 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459215
Principal investigator 1 Incyte Corporation $15.84 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459217
Principal investigator 1 Incyte Corporation $211.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459285
Principal investigator 1 Incyte Corporation $95.00 07/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472823
Principal investigator 1 EMD Serono, Inc. $69.79 06/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703031077
Principal investigator 1 Incyte Corporation $170,414.88 06/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies No dispute reported 06/30/2026 666458785
Principal investigator 1 Incyte Corporation $282,407.89 06/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666458783
Principal investigator 1 Incyte Corporation $20.26 06/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459185
Principal investigator 1 Incyte Corporation $117.00 06/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459187
Principal investigator 1 Incyte Corporation $47.75 06/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459189
Principal investigator 1 Merck Sharp & Dohme Corporation $132,942.88 06/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 691455301
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666467495
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472821
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472841
Principal investigator 1 EMD Serono, Inc. $1,441.60 05/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703034069
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703034515
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,874.50 05/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase IIB TMB High Pan Tumor Monotherapy No dispute reported 06/30/2026 639761851
Principal investigator 1 Incyte Corporation $47.75 05/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459181
Principal investigator 1 Incyte Corporation $114.60 05/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459183
Principal investigator 1 Incyte Corporation $47.75 05/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459195
Principal investigator 1 Incyte Corporation $47.75 05/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459197
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500927
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501009
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501011
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501013
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501015
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501017
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501019
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501021
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501023
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501025
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501027
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501029
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501031
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501033
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501035
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501037
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501039
Principal investigator 1 Incyte Corporation $315.00 05/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501041
Principal investigator 1 Incyte Corporation $77.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500917
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500919
Principal investigator 1 Incyte Corporation $7.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500921
Principal investigator 1 Incyte Corporation $21.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500923
Principal investigator 1 Incyte Corporation $63.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500925
Principal investigator 1 Incyte Corporation $77.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500977
Principal investigator 1 Incyte Corporation $77.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500979
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500981
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500983
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500985
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500987
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500989
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500991
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500993
Principal investigator 1 Incyte Corporation $5.60 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500995
Principal investigator 1 Incyte Corporation $7.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500997
Principal investigator 1 Incyte Corporation $7.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500999
Principal investigator 1 Incyte Corporation $21.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501001
Principal investigator 1 Incyte Corporation $21.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501003
Principal investigator 1 Incyte Corporation $63.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501005
Principal investigator 1 Incyte Corporation $63.00 05/03/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666501007
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666467493
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472819
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472835
Principal investigator 1 Incyte Corporation $74,719.80 04/30/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459381
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500877
Principal investigator 1 Incyte Corporation $7.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500879
Principal investigator 1 Incyte Corporation $21.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500881
Principal investigator 1 Incyte Corporation $63.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500883
Principal investigator 1 Incyte Corporation $35.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500885
Principal investigator 1 Incyte Corporation $77.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500887
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500889
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500891
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500893
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500895
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500897
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500899
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500901
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500903
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500905
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500907
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500909
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500911
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500913
Principal investigator 1 Incyte Corporation $5.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500915
Principal investigator 1 Incyte Corporation $7.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500937
Principal investigator 1 Incyte Corporation $7.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500939
Principal investigator 1 Incyte Corporation $7.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500941
Principal investigator 1 Incyte Corporation $7.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500943
Principal investigator 1 Incyte Corporation $21.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500945
Principal investigator 1 Incyte Corporation $21.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500947
Principal investigator 1 Incyte Corporation $21.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500949
Principal investigator 1 Incyte Corporation $21.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500951
Principal investigator 1 Incyte Corporation $63.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500953
Principal investigator 1 Incyte Corporation $63.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500955
Principal investigator 1 Incyte Corporation $63.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500957
Principal investigator 1 Incyte Corporation $63.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500959
Principal investigator 1 Incyte Corporation $35.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500961
Principal investigator 1 Incyte Corporation $35.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500963
Principal investigator 1 Incyte Corporation $35.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500965
Principal investigator 1 Incyte Corporation $35.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500967
Principal investigator 1 Incyte Corporation $77.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500969
Principal investigator 1 Incyte Corporation $77.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500971
Principal investigator 1 Incyte Corporation $77.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500973
Principal investigator 1 Incyte Corporation $77.00 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies No dispute reported 06/30/2026 666500975
Principal investigator 1 Incyte Corporation $70.32 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459153
Principal investigator 1 Incyte Corporation $65.89 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459155
Principal investigator 1 Incyte Corporation $377.16 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459157
Principal investigator 1 Incyte Corporation $754.32 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459159
Principal investigator 1 Incyte Corporation $46.80 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459161
Principal investigator 1 Incyte Corporation $28.65 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459163
Principal investigator 1 Incyte Corporation $60.80 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459165
Principal investigator 1 Incyte Corporation $12.32 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459167
Principal investigator 1 Incyte Corporation $70.50 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459169
Principal investigator 1 Incyte Corporation $38.20 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459171
Principal investigator 1 Incyte Corporation $6.12 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459173
Principal investigator 1 Incyte Corporation $131.78 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459175
Principal investigator 1 Incyte Corporation $40.88 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459177
Principal investigator 1 Incyte Corporation $183.06 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459179
Principal investigator 1 Incyte Corporation $70.32 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459191
Principal investigator 1 Incyte Corporation $70.50 04/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666459193
Principal investigator 1 Incyte Corporation $22,790.75 04/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies No dispute reported 06/30/2026 666458705
Principal investigator 1 EMD Serono, Inc. $15,773.00 04/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703036815
Principal investigator 1 EMD Serono, Inc. $46,419.68 04/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703037157
Principal investigator 1 Incyte Corporation $4,094.45 04/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458699
Principal investigator 1 Incyte Corporation $3,453.55 04/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458701
Principal investigator 1 Incyte Corporation $333,178.20 04/02/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459375
Principal investigator 1 Incyte Corporation $52,391.70 04/02/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459377
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666467491
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472817
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472829
Principal investigator 1 Merck Sharp & Dohme Corporation $203,653.50 03/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 691536825
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,052.55 03/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase IIB TMB High Pan Tumor Monotherapy No dispute reported 06/30/2026 639761853
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,995.72 03/20/2019 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
MEDI1873 GITRL Solid Tmr-D6150C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 685003929
Principal investigator 1 Incyte Corporation $1,994.10 03/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666458679
Principal investigator 1 Incyte Corporation $19,273.50 03/12/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459359
Principal investigator 1 Incyte Corporation $28.65 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459075
Principal investigator 1 Incyte Corporation $263.56 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459117
Principal investigator 1 Incyte Corporation $754.32 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459119
Principal investigator 1 Incyte Corporation $117.50 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459123
Principal investigator 1 Incyte Corporation $76.40 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459129
Principal investigator 1 Incyte Corporation $105.90 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459131
Principal investigator 1 Incyte Corporation $30.30 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459133
Principal investigator 1 Incyte Corporation $8.80 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459135
Principal investigator 1 Incyte Corporation $101.70 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459137
Principal investigator 1 Incyte Corporation $3.15 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459139
Principal investigator 1 EMD Serono, Inc. $1,621.80 03/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703034303
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666467499
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472637
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472653
Principal investigator 1 EMD Serono, Inc. $113.39 02/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS2014080005 No dispute reported 06/30/2026 703031729
Principal investigator 1 EMD Serono, Inc. $113.39 02/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS2014080005 No dispute reported 06/30/2026 703031731
Principal investigator 1 Merck Sharp & Dohme Corporation $67,884.50 02/26/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 691296327
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $326.63 02/25/2019 Non-covered Recipient Entity
University Of Texas Md Anderson Cancer Center
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 639761849
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,991.25 02/25/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 640706613
Principal investigator 1 EMD Serono, Inc. $3,594.00 02/20/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS 201408-0005 No dispute reported 06/30/2026 703035433
Principal investigator 1 Incyte Corporation $20,500.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459349
Principal investigator 1 Incyte Corporation $750.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459351
Principal investigator 1 Incyte Corporation $7,000.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459353
Principal investigator 1 Incyte Corporation $1,000.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459355
Principal investigator 1 Incyte Corporation $1,500.00 02/14/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459357
Principal investigator 1 Eli Lilly and Company $2,240,853.08 02/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 654287885
Principal investigator 1 Incyte Corporation $650.00 02/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459341
Principal investigator 1 Incyte Corporation $848.00 02/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459343
Principal investigator 1 Incyte Corporation $100.00 02/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459345
Principal investigator 1 Incyte Corporation $250.00 02/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459347
Principal investigator 1 Incyte Corporation $121,872.75 02/06/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies No dispute reported 06/30/2026 666458697
Principal investigator 1 Incyte Corporation $23,255.10 02/05/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459339
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666467497
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472635
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472647
Principal investigator 1 EMD Serono, Inc. $113.39 01/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS2014080005 No dispute reported 06/30/2026 703031733
Principal investigator 1 EMD Serono, Inc. $113.39 01/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS2014080005 No dispute reported 06/30/2026 703031735
Principal investigator 1 Novartis Pharmaceuticals Corporation $299,458.95 01/31/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 640708665
Principal investigator 1 Incyte Corporation $93.60 01/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459065
Principal investigator 1 Incyte Corporation $162.72 01/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459067
Principal investigator 1 Incyte Corporation $169.44 01/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459069
Principal investigator 1 Incyte Corporation $93.60 01/28/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459079
Principal investigator 1 EMD Serono, Inc. $1,621.80 01/22/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
EMR 200647-001 No dispute reported 06/30/2026 703034301
Principal investigator 1 EMD Serono, Inc. $31,250.00 01/21/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS 201408-0005 No dispute reported 06/30/2026 703037079
Principal investigator 1 EMD Serono, Inc. $9,419.00 01/18/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MS 201408-0005 No dispute reported 06/30/2026 703036427
Principal investigator 1 Incyte Corporation $60.00 01/17/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666458691
Principal investigator 1 Incyte Corporation $350.00 01/17/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666458693
Principal investigator 1 Incyte Corporation $2,579.00 01/17/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459335
Principal investigator 1 Incyte Corporation $19,733.00 01/17/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 No dispute reported 06/30/2026 666459337
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,346.10 01/16/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 No dispute reported 06/30/2026 639761847
Principal investigator 1 Incyte Corporation $22,566.60 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459325
Principal investigator 1 Incyte Corporation $7,000.00 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459327
Principal investigator 1 Incyte Corporation $21,250.00 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459329
Principal investigator 1 Incyte Corporation $1,000.00 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459331
Principal investigator 1 Incyte Corporation $1,500.00 01/15/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 666459333
Principal investigator 1 Incyte Corporation $48,853.80 01/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459321
Principal investigator 1 Incyte Corporation $20,447.10 01/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666459323
Principal investigator 1 Novartis Pharmaceuticals Corporation $84,282.38 01/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
OPEN LABEL MULTICENTER PHASE L AND OR LL STUDY OF THE SAFETY AND EFFICACY OF PDR001 ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 640708661
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,756.00 01/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 640706609
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472629
Principal investigator 1 Incyte Corporation $16.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472631
Principal investigator 1 Incyte Corporation $38.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472633
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 666472639
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666472641
Principal investigator 1 Novartis Pharmaceuticals Corporation $140.00 01/01/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF ORAL FGF401 IN ADULT PATIENTS WITH HEPATOCELLULAR CARCINOMA OR SOLID MALIGNANCIES CHARACTERIZED BY POSITIVE FGFR4 AND KLB EXPRESSION No dispute reported 06/30/2026 640729987